GLP-2TZ is a synthetic peptide based on the native GIP sequence, modified to incorporate dual agonist activity at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), with a C20 fatty diacid moiety enabling albumin binding for once-weekly dosing. Its mechanism involves biased agonism toward the cAMP signaling pathway at both receptors, with combinatorial activation producing synergistic effects on glucose-stimulated insulin secretion, glucagon suppression, and gastric emptying delay that exceed outcomes observed with selective GLP-1R agonists alone. Phase 3 SURPASS clinical trial data demonstrated significant HbA1c and body weight reductions across dose levels, with GLP-2TZ receiving FDA approval in 2022 and currently under investigation for obesity, heart failure, sleep apnea, and non-alcoholic steatohepatitis. Supplied as lyophilized powder, ≥99% purity. Store at -20°C. Research use only. Not for human consumption.